STOCK TITAN

PetIQ, Inc. Announces Results of Special Meeting of Stockholders

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

PetIQ, Inc. (Nasdaq: PETQ), a leading pet medication, health and wellness company, announced that approximately 80% of its outstanding shares voted to approve the adoption of the definitive merger agreement with Bansk Group. The all-cash transaction, valued at approximately $1.5 billion, will result in Bansk Group acquiring all outstanding shares of PetIQ's common stock for $31.00 per share.

The company anticipates a closing date of October 25, 2024. Upon completion of the transaction, PetIQ's common stock will be delisted from the NASDAQ Stock Market, and the company will become privately held. PetIQ will continue to be operated independently by its current executive team. Cord Christensen, Founder, Chairman and CEO of PetIQ, expressed excitement about the stockholders' approval and the partnership with Bansk Group.

PetIQ, Inc. (Nasdaq: PETQ), una delle principali aziende nel settore dei farmaci e della salute per animali domestici, ha annunciato che circa l'80% delle sue azioni in circolazione ha votato a favore dell'adozione dell'accordo di fusione definitivo con Bansk Group. La transazione completamente in contante, del valore approssimativo di 1,5 miliardi di dollari, porterà Bansk Group ad acquisire tutte le azioni in circolazione delle azioni ordinarie di PetIQ per 31,00 dollari per azione.

L'azienda prevede una data di chiusura il 25 ottobre 2024. Al termine della transazione, le azioni ordinarie di PetIQ saranno escluse dal NASDAQ Stock Market, e l'azienda diventerà di proprietà privata. PetIQ continuerà ad essere gestita in modo indipendente dal suo attuale team dirigenziale. Cord Christensen, Fondatore, Presidente e CEO di PetIQ, ha espresso entusiasmo per l'approvazione degli azionisti e per la partnership con Bansk Group.

PetIQ, Inc. (Nasdaq: PETQ), una de las principales empresas en medicamentos, salud y bienestar para mascotas, anunció que aproximadamente el 80% de sus acciones en circulación votó a favor de la adopción del acuerdo de fusión definitivo con Bansk Group. La transacción en efectivo, valorada en aproximadamente 1.5 mil millones de dólares, resultará en que Bansk Group adquiera todas las acciones en circulación de la acción común de PetIQ por 31,00 dólares por acción.

La compañía anticipa una fecha de cierre para el 25 de octubre de 2024. Al completar la transacción, las acciones comunes de PetIQ serán deslistadas de NASDAQ Stock Market y la empresa se convertirá en privada. PetIQ continuará siendo operada de forma independiente por su actual equipo ejecutivo. Cord Christensen, Fundador, Presidente y CEO de PetIQ, expresó su entusiasmo por la aprobación de los accionistas y la asociación con Bansk Group.

PetIQ, Inc. (Nasdaq: PETQ)는 반려동물 약품, 건강 및 웰빙 분야의 선도적인 기업으로, 약 80%의 주식이 Bansk Group과의 최종 합병 계약 채택에 찬성하여 투표했다고 발표했습니다. 이 현금 거래는 약 15억 달러로 평가되며, Bansk Group은 PetIQ의 보통주를 주당 31.00 달러에 인수하게 됩니다.

회사는 거래 종료일을 2024년 10월 25일로 예상하고 있습니다. 거래가 완료되면 PetIQ의 보통주는 NASDAQ 증권 거래소에서 상장 폐지되며 회사는 비상장 기업으로 전환됩니다. PetIQ는 현재의 경영진 팀에 의해 독립적으로 운영될 것입니다. PetIQ의 설립자이자 회장이며 CEO인 Cord Christensen은 주주들의 승인과 Bansk Group과의 파트너십에 대해 기대감을 표명했습니다.

PetIQ, Inc. (Nasdaq: PETQ), une entreprise leader dans le domaine des médicaments, de la santé et du bien-être des animaux de compagnie, a annoncé qu'environ 80 % de ses actions en circulation ont voté en faveur de l'adoption de l'accord de fusion définitif avec Bansk Group. La transaction entièrement en espèces, d'une valeur d'environ 1,5 milliard de dollars, entraînera l'acquisition par Bansk Group de toutes les actions ordinaires en circulation de PetIQ au prix de 31,00 dollars par action.

L'entreprise anticipe une date de clôture au 25 octobre 2024. Une fois la transaction réalisée, les actions ordinaires de PetIQ seront radiées de la bourse NASDAQ, et l'entreprise deviendra privée. PetIQ continuera d'être exploitée de manière indépendante par son équipe de direction actuelle. Cord Christensen, fondateur, président et PDG de PetIQ, a exprimé son enthousiasme pour l'approbation des actionnaires et le partenariat avec Bansk Group.

PetIQ, Inc. (Nasdaq: PETQ), ein führendes Unternehmen im Bereich Tiermedizin, Gesundheit und Wellness, gab bekannt, dass etwa 80% der ausgegebenen Aktien für die Annahme des endgültigen Fusionsvertrags mit Bansk Group gestimmt haben. Die Bartransaktion, die mit etwa 1,5 Milliarden Dollar bewertet wird, wird dazu führen, dass Bansk Group alle ausgegebenen Aktien von PetIQ zum Preis von 31,00 Dollar pro Aktie erwerben wird.

Das Unternehmen erwartet einen Abschlussdatum am 25. Oktober 2024. Nach Abschluss der Transaktion wird die Stammaktie von PetIQ von der NASDAQ-Börse delistet, und das Unternehmen wird privat gehalten. PetIQ wird weiterhin unabhängig von seinem aktuellen Führungsteam betrieben. Cord Christensen, Gründer, Vorsitzender und CEO von PetIQ, äußerte seine Begeisterung über die Genehmigung der Aktionäre und die Partnerschaft mit Bansk Group.

Positive
  • Merger agreement with Bansk Group approved by 80% of outstanding shares
  • All-cash transaction valued at approximately $1.5 billion
  • $31.00 per share offer price for PetIQ's common stock
  • Company will continue to be operated independently by current executive team after going private
Negative
  • PetIQ's common stock will be delisted from NASDAQ Stock Market
  • Company will transition from public to private ownership

Insights

The approval of PetIQ's merger with Bansk Group marks a significant milestone for the company and its shareholders. With approximately 80% of outstanding shares voting in favor, there's strong support for this $1.5 billion all-cash transaction. The $31.00 per share offer represents a substantial premium, likely reflecting Bansk Group's confidence in PetIQ's market position and growth potential in the pet health and wellness sector.

This deal will take PetIQ private, potentially allowing for more flexible long-term strategies without the pressures of quarterly reporting. However, current public shareholders will lose future upside potential in this growing market. The transaction's size and the involvement of a private equity firm suggest expectations of significant value creation in the pet care industry.

For investors, this deal highlights the attractiveness of the pet care market, which has shown resilience even in challenging economic times. It may prompt a reassessment of valuations for other publicly traded pet care companies, potentially driving up stock prices in the sector.

The PetIQ-Bansk Group merger reflects broader trends in the pet care industry. The $1.5 billion valuation underscores the sector's robust growth prospects, driven by increasing pet ownership and higher spending on pet health and wellness. This transaction could trigger a wave of consolidation in the fragmented pet care market as companies seek scale and competitive advantages.

The deal's structure, maintaining PetIQ's independent operations under private ownership, suggests Bansk Group sees value in the company's existing business model and management team. This approach could allow for accelerated expansion and innovation without the constraints of public market scrutiny.

For the pet care industry, this merger signals strong investor confidence and may attract more capital to the sector. It could lead to increased competition, potentially benefiting consumers through more affordable pet healthcare options, aligning with PetIQ's mission. Investors should watch for ripple effects across the industry, including potential stock price movements for comparable companies and increased M&A activity.

Reports Merger Agreement with Bansk Group Approved by Stockholders and Anticipates a Closing Date of October 25, 2024

EAGLE, Idaho, Oct. 22, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, announced today that at its virtual Special Meeting of Stockholders approximately 80% of its outstanding shares of common stock voted to approve the adoption of the definitive merger agreement (the “Agreement”) pursuant to which Bansk Group will acquire all of the outstanding shares of PetIQ’s common stock for $31.00 per share, in an all-cash transaction valued at approximately $1.5 billion.

“On behalf of PetIQ’s Board of Directors, we are excited to announce stockholders’ approval of our proposed transaction with Bansk Group, representing an important milestone for our anticipated closing on October 25, 2024,” commented Cord Christensen, Founder, Chairman and CEO of PetIQ. “We look forward to partnering with the team at Bansk Group as we continue to execute on PetIQ’s mission of providing pet parents convenient access to affordable pet healthcare to support the Company’s continued success.”

Upon completion of the proposed transaction, PetIQ’s common stock will no longer be listed on the NASDAQ Stock Market, and PetIQ will be privately held and continue to be operated independently by the Company’s executive team.

For further information regarding PetIQ’s final vote results, as certified by the independent inspector of elections, please see PetIQ's Current Report on Form 8-K, which will be filed in connection with this announcement.

About PetIQ

PetIQ is a leading pet medication, health and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable products and veterinary services. The Company's product business engages with pet parents through retail and e-commerce sales channels with its branded and distributed pet medications as well as health and wellness items. PetIQ manufactures and distributes pet products from its world-class facilities in Omaha, Nebraska, Springville, Utah and Daytona Beach, Florida. The Company’s veterinarian services offering operates in over 2,600 mobile community clinic locations and wellness centers hosted at retail partners in 39 states. PetIQ believes that pets are an important part of the family and deserve the best products and care we can provide them.

Investor contact
katie.turner@petiq.com or 208.513.1513

Media contact
kara.schafer@petiq.com or 407.929.6727

Notice Regarding Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the benefits of and timeline for closing the proposed transaction with Bansk Group. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Company management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including the risk of the occurrence of any event, change or other circumstances that could give rise to the termination of the Agreement; and the risk that the parties to the Agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all.

Further information on factors that could cause actual results to differ materially from the results anticipated by the forward-looking statements is included in the definitive proxy statement filed by the Company with the Securities and Exchange Commission on September 16, 2024, in connection with the Agreement, the Company’s Annual Report on Form 10‑K for the fiscal year ended December 31, 2023, Quarterly Reports on Form 10‑Q, Current Reports on Form 8‑K and other filings made by the Company from time to time with the Securities and Exchange Commission. These filings, when available, are available on the investor relations section of the Company’s website at https://ir.petiq.com/ or on the SEC’s website at https://www.sec.gov. If any of these risks materialize or any of these assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently does not know of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.


FAQ

What was the outcome of PetIQ's (PETQ) Special Meeting of Stockholders?

Approximately 80% of PetIQ's outstanding shares voted to approve the adoption of the definitive merger agreement with Bansk Group.

What is the value of the merger agreement between PetIQ (PETQ) and Bansk Group?

The all-cash transaction is valued at approximately $1.5 billion, with Bansk Group acquiring PetIQ's outstanding shares for $31.00 per share.

When is the anticipated closing date for PetIQ's (PETQ) merger with Bansk Group?

The anticipated closing date for the merger is October 25, 2024.

What will happen to PetIQ's (PETQ) stock listing after the merger?

Upon completion of the transaction, PetIQ's common stock will be delisted from the NASDAQ Stock Market, and the company will become privately held.

PetIQ, Inc.

NASDAQ:PETQ

PETQ Rankings

PETQ Latest News

PETQ Stock Data

918.69M
27.82M
7%
102%
3.42%
Drug Manufacturers - Specialty & Generic
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States of America
EAGLE